All In Biotech

Drug Trial Radar · NCT07016516

A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PRT-064040 Nasal Spray in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Jun 7, 2025

Primary completion

Sep 8, 2025

Study completion Sep 8, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 11, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is a Phase I, single-center, randomized, double-blind, placebo-controlled study conducted in healthy Chinese adult subjects. The purpose of this study is to learn about: * Safety and tolerability of PRT-064040 nasal spray in healthy adult subjects. * Pharmacokinetics after single and multiple dose of PRT-064040 nasal spray in healthy Chinese adult subjects. This study is divided into two parts: * Eligible subjects in Part A will receive a single dose of PRT-064040 nasal spray or placebo. * Eligible subjects in Part B will receive multiple doses of PRT-064040 nasal spray or placebo, administered once daily (QD) for a total of 7 consecutive days.

Conditions

  • Migraine

Interventions

  • PRT-064040 nasal sprayDrug

    A single dose of PRT-064040 nasal spray at one of six dose levels

  • PlaceboDrug

    A single dose of Placebo at one of six dose levels

  • PRT-064040 nasal sprayDrug

    Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days

  • PlaceboDrug

    Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence and severity of adverse eventsTime frame: From first dose to maximum of 2 days post last dose administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Third Hospital of Changsha

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.